Sorafenib is currently the only targeted therapy available for advanced stage hepatocellular carcinoma (HCC). Cutaneous adverse events associated with sorafenib treatment include hand-foot skin reaction, but there has been no report of drug reaction (or rash) with eosinophilia and systemic symptoms (DRESS) syndrome. Here, we report a case of 72-year-old man with HCC and alcoholic liver cirrhosis who developed skin eruptions, fever, eosinophilia, and deteriorated hepatic and renal function under sorafenib treatment. He has since successfully recovered with conservative care. (Korean J Gastroenterol 2016;67:337-340
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepat...
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-thr...
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma relate...
Sorafenib (NexavarⓇ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has re...
Abstract Introduction Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for th...
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its re...
Sorafenib which is used in the treatment of renal, thyroid and hepatocellular cancers is a multi-tar...
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell ...
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable ...
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalu...
Background:We report two cases in which severe skin disorders developed during sorafenib treatment i...
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanc...
Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosi...
Sorafenib is currently the gold standard therapy for palliative treatment of advanced hepatocellular...
Sorafenib is a novel small molecule multiple kinase inhibitor which has been used for metastatic ren...
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepat...
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-thr...
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma relate...
Sorafenib (NexavarⓇ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has re...
Abstract Introduction Sorafenib, an oral multitargeted tyrosine kinase inhibitor, is licensed for th...
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its re...
Sorafenib which is used in the treatment of renal, thyroid and hepatocellular cancers is a multi-tar...
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell ...
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable ...
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalu...
Background:We report two cases in which severe skin disorders developed during sorafenib treatment i...
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanc...
Introduction. Sorafenib is an oral multikinase inhibitor that targets Raf kinase and receptor tyrosi...
Sorafenib is currently the gold standard therapy for palliative treatment of advanced hepatocellular...
Sorafenib is a novel small molecule multiple kinase inhibitor which has been used for metastatic ren...
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepat...
Drug rash with eosinophilia and systemic symptoms (DRESS syndrome) is a severe, potentially life-thr...
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma relate...